Results 111 to 120 of about 6,644,019 (302)

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Climate change and infectious disease risk management: a localised health security perspective [PDF]

, 2008
Pathogenic risks in relation to climate change are not fully understood and to a large extent have to be regarded as unpredictable. It is therefore important to focus attention on human vulnerability and coping for which more certain influences on ...
Collins, Andrew
core   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Exquisite selectivity of griselimycin extends to beta subunit of DNA polymerases from Gram-negative bacterial pathogens

Communications Biology
Griselimycin, a cyclic depsidecapeptide produced by Streptomyces griseus, is a promising lead inhibitor of the sliding clamp component of bacterial DNA polymerases (β-subunit of Escherichia coli DNA pol III).
Michael K. Fenwick, Phillip G. Pierce, Jan Abendroth, Kayleigh F. Barrett, Lynn K. Barrett, Kalinga Bowatte, Ryan Choi, Ian Chun, Deborah G. Conrady, Justin K. Craig, David M. Dranow, Bradley Hammerson, Tate Higgins, Donald D. Lorimer, Peer Lukat, Stephen J. Mayclin, Stephen Nakazawa Hewitt, Ying Po Peng, Ashwini Shanbhogue, Hayden Smutney, Matthew Z. Z. Stigliano, Logan M. Tillery, Hannah S. Udell, Ellen G. Wallace, Amy E. DeRocher, Isabelle Q. Phan, Bart L. Staker, Sandhya Subramanian, Wesley C. Van Voorhis, Wulf Blankenfeldt, Rolf Müller, Thomas E. Edwards, Peter J. Myler   +32 more
doaj   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization

Molecular Oncology, EarlyView.
In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu, Nicolas J. Niklaus, Anna M. Schläfli, Igor Tokarchuk, Magali Humbert, Federico La Manna, Bich Vu, David Maul, Ramin Radpour, Marianna Kruithof‐de Julio, Inti Zlobec, Jörn Dengjel, Bruce E. Torbett, Mario P. Tschan   +13 more
wiley   +1 more source

Clinical Value of Complement C3a, C5a, and sC5b-9 in Evaluating the Severity of Patients with Severe Fever with Thrombocytopenia Syndrome

Journal of Inflammation Research
Tianyan Chen,1,* Yawen Liu,2,* Yuan Liu,1 Nannan Hu,1 Yan Dai,1 Chuanlong Zhu,1 Yaping Han,1 Ke Jin,1 Jun Li1 1Department of Infectious Disease, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, People’s ...
Chen T, Liu Y, Liu Y, Hu N, Dai Y, Zhu C, Han Y, Jin K, Li J   +8 more
doaj  

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Multidrug-Resistant Elizabethkingia anophelis Bacteremia in Northern Taiwan: Focusing on Prognostic Factors and Antimicrobial Susceptibility to Minocycline and Rifampin

Infection and Drug Resistance
Wei-Lun Chuang,1,2,* Fu-Chieh Chang,2,3,* Chien-Feng Kuo,1,2 Chih-Chen Lin1,2 1Department of Infectious Diseases, MacKay Memorial Hospital, Taipei City, Taiwan; 2Infection Control Center, MacKay Memorial Hospital, Taipei City, Taiwan ...
Chuang WL, Chang FC, Kuo CF, Lin CC
doaj  

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source